{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T07:04:02Z","timestamp":1749884642414,"version":"3.37.3"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Obstructive sleep apnea (OSA) is associated with an increased incidence of atrial fibrillation (AF), hypertension, diabetes, heart failure, coronary heart disease, stroke, and death. We sought to evaluate the effectiveness and safety of rivaroxaban versus warfarin in nonvalvular AF (NVAF) patients with concomitant OSA.<\/jats:p><jats:p>\n          Methods\u2003This was an analysis of electronic health record (EHR) data from November 2010 to December 2021. We included adults with NVAF and OSA at baseline, newly initiated on rivaroxaban or warfarin, and with \u226512 months of prior EHR activity. Patients with valvular disease, alternative indications for oral anticoagulation, or who were pregnant were excluded. The incidence rates of developing stroke or systemic embolism (SSE) and bleeding-related hospitalization were evaluated. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using propensity score-overlap weighted proportional hazards regression. Multiple sensitivity and subgroup analyses were performed.<\/jats:p><jats:p>\n          Results\u2003We included 21,940 rivaroxaban (20.1% at the 15\u2009mg dose) and 38,213 warfarin (time-in-therapeutic range\u2009=\u200947.3\u2009\u00b1\u200928.3%) patients. Rivaroxaban was found to have similar hazard of SSE compared to warfarin (HR\u2009=\u20090.92, 95% CI\u2009=\u20090.82\u20131.03). Rivaroxaban was associated with a reduced rate of bleeding-related hospitalizations (HR\u2009=\u20090.85, 95% CI\u2009=\u20090.78\u20130.92) versus warfarin, as well as reductions in intracranial (HR\u2009=\u20090.76, 95% CI\u2009=\u20090.62\u20130.94) and extracranial (HR\u2009=\u20090.89, 95%CI\u2009=\u20090.81\u20130.97) bleeding. Upon sensitivity analysis restricting the population to men with a CHA2DS2VASc score \u22652 or women with a score \u22653, rivaroxaban was associated with a significant 33% risk reduction in SSE and 43% reduction in the risk of bleeding-related hospitalization. No significant interaction for the SSE or bleeding-related hospitalization outcomes was observed upon subgroup analyses.<\/jats:p><jats:p>\n          Conclusion\u2003Among patients with NVAF and OSA, rivaroxaban had similar SSE risk versus warfarin but was associated with reductions in any intracranial and extracranial bleeding-related hospitalizations. Rivaroxaban was associated with significant reductions in SSE and bleeding-related hospitalizations when the study population was restricted to patients with a moderate-to-high risk of SSE. These data should provide prescribers with additional confidence in selecting rivaroxaban in NVAF patients who have OSA at the time of anticoagulation initiation.<\/jats:p>","DOI":"10.1055\/a-2013-3346","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T23:29:35Z","timestamp":1673738975000},"page":"e82-e93","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness and Safety of Rivaroxaban Versus Warfarin among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea"],"prefix":"10.1055","volume":"07","author":[{"given":"Nitesh","family":"Sood","sequence":"additional","affiliation":[{"name":"Arrhythmia Services, Southcoast Health, Massachusetts, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Ashton","sequence":"additional","affiliation":[{"name":"Real World Value and Evidence, Janssen Scientific Affairs LLC, Titusville, New Jersey, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Bessada","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Connecticut, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Galli","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Connecticut, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brahim K.","family":"Bookhart","sequence":"additional","affiliation":[{"name":"Real World Value and Evidence, Janssen Scientific Affairs LLC, Titusville, New Jersey, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-7158","authenticated-orcid":false,"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Connecticut, United States"},{"name":"Evidence-Based Practice Center, Hartford Hospital, Hartford, Connecticut, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"C T January","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"ref2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.2020.3514","article-title":"Diagnosis and management of obstructive sleep apnea: a review","volume":"323","author":"D J Gottlieb","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14779072.2018.1515013","article-title":"Strategies to manage obstructive sleep apnea to decrease the burden of atrial fibrillation","volume":"16","author":"C M Goes","year":"2018","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jamacardio.2018.0095","article-title":"Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review","volume":"3","author":"D Linz","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.chest.2016.09.014","article-title":"OSA and cardiac arrhythmogenesis: mechanistic insights","volume":"151","author":"A M May","year":"2017","journal-title":"Chest"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2011.02.343","article-title":"Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation","volume":"108","author":"C Y Ng","year":"2011","journal-title":"Am J Cardiol"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.amjcard.2012.03.037","article-title":"Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter","volume":"110","author":"K Monahan","year":"2012","journal-title":"Am J Cardiol"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjcard.2014.11.027","article-title":"Effect of obstructive sleep apnea on frequency of stroke in patients with atrial fibrillation","volume":"115","author":"D M Yaranov","year":"2015","journal-title":"Am J Cardiol"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/STROKEAHA.120.030285","article-title":"Impact of sleep apnea on cardioembolic risk in patients with atrial fibrillation: data from the ESADA Cohort","volume":"52","author":"M F Pengo","year":"2021","journal-title":"Stroke"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ahj.2014.12.024","article-title":"Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation\u2014results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"169","author":"F Holmqvist","year":"2015","journal-title":"Am Heart J"},{"issue":"S 01","key":"ref11","first-page":"302","article-title":"Sleep apnea and risk of ischemic stroke in patients with atrial fibrillation","volume":"37","author":"H Koch","year":"2016","journal-title":"Eur Heart J"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jphs.2018.07.002","article-title":"Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia","volume":"137","author":"H Imano","year":"2018","journal-title":"J Pharmacol Sci"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5664\/jcsm.8160","article-title":"Multisite validation of a simple electronic health record algorithm for identifying diagnosed obstructive sleep apnea","volume":"16","author":"B T Keenan","year":"2020","journal-title":"J Clin Sleep Med"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/jsr.12465","article-title":"Validity of administrative data for identification of obstructive sleep apnea","volume":"26","author":"C R Laratta","year":"2017","journal-title":"J Sleep Res"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"P C Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"A Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"H Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study","volume":"391","author":"T Gilbert","year":"2018","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"J A Sterne","year":"2009","journal-title":"BMJ"},{"issue":"23","key":"ref22","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"L E Thomas","year":"2020","journal-title":"JAMA"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"A Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"S M Langan","year":"2018","journal-title":"BMJ"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijcard.2015.11.158","article-title":"Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea","volume":"204","author":"F M Szymanski","year":"2016","journal-title":"Int J Cardiol"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12933-021-01250-5","article-title":"Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin","volume":"20","author":"C I Coleman","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3390\/jcm9061633","article-title":"Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES Study","volume":"9","author":"S Deitelzweig","year":"2020","journal-title":"J Clin Med"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"e0245392","DOI":"10.1371\/journal.pone.0245392","article-title":"Obstructive sleep apnea: a sharp increase in the prevalence of patients treated with nasal CPAP over the last decade in France","volume":"16","author":"L Mandereau-Bruno","year":"2021","journal-title":"PLoS One"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/resp.13838","article-title":"Global burden of sleep-disordered breathing and its implications","volume":"25","author":"M M Lyons","year":"2020","journal-title":"Respirology"},{"issue":"07","key":"ref33","doi-asserted-by":"crossref","first-page":"773","DOI":"10.5664\/jcsm.4858","article-title":"Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015","volume":"11","author":"K Ramar","year":"2015","journal-title":"J Clin Sleep Med"},{"issue":"03","key":"ref34","first-page":"244","article-title":"Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States","volume":"15","author":"W L Baker","year":"2009","journal-title":"J Manag Care Pharm"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2013-3346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T23:59:12Z","timestamp":1680134352000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2013-3346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":31,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,1,7]]},"published-print":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2013-3346","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"type":"electronic","value":"2512-9465"}],"subject":[],"published-other":{"date-parts":[[2023,1,14]]},"published":{"date-parts":[[2023,1]]}}}